Ropes & Gray advised EQRx in the deal.
EQRx announced a partnership to leverage Germany-based Evotec’s data-driven integrated drug discovery and development platform across different drug modalities and therapeutic areas in oncology and immunology.
Under the agreement, EQRx and Evotec will collaborate on drug discovery and pre-clinical development, while EQRx will be responsible for clinical development, regulatory and commercialization efforts.
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers.
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients.
The Ropes & Gray team was led by life sciences partner Abigail Gregor (Picture; Boston).
Involved fees earner: Abigail Gregor – Ropes & Gray;
Law Firms: Ropes & Gray;